Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLPP | Q16740 | 5/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | MAOB | P27338 | 4/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | GPR18 | Q14330 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6699940 | 0.94 | MAPK1 (0.34) | CLPPMAPK1MAOBADORA2ATLR7 | |
| SCHEMBL6699350 | 0.90 | P2RX7 (0.35) | MAPK1MAOBADORA2AP2RX7 | |
| SCHEMBL6818788 | 0.84 | NPSR1 (0.38) | CLPPGPR18 | |
| SCHEMBL6699931 | 0.80 | CLPP (0.38) | CLPPMAPK1MAOBADORA2ATP53 | |
| SCHEMBL6700606 | 0.80 | CLPP (0.38) | CLPPMAPK1P2RX7TP53 | |
| SCHEMBL6703428 | 0.79 | ALDH1A1 (0.39) | CLPPMAPK1TLR7PARP1PARP2 | |
| SCHEMBL6700327 | 0.78 | CLPP (0.43) | CLPP | |
| SCHEMBL6706967 | 0.74 | MMP13 (0.38) | CLPP | |
| SCHEMBL6696647 | 0.74 | CLPP (0.35) | CLPPMAPK1 | |
| SCHEMBL6698925 | 0.73 | MAPK1 (0.35) | CLPPMAPK1MAOBADORA2AP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040038994-A1 | Pyrimidine fused bicyclic metalloproteinase inhibitors | WILSON MICHAEL WILLIAM (US) | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038994-A1 | Pyrimidine fused bicyclic metalloproteinase inhibitors | MMP9, MMP1, MMP2 | CLPP 3282/4885MAPK1 1571/4885MAOB 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.